Company intelligence / Profile preview

EBR Systems

Sunnyvale, California, United Statesebrsystemsinc.com ↗

Ownership: Private
Development stage: Phase 3

Overview

The WiSE CRT System has demonstrated positive clinical results. In a European study of 35 patients, biventricular pacing was achieved in 97% of participants one month after implant. The pivotal U.S. SOLVE-CRT trial stopped early due to positive interim results and supported FDA approval in April 2025. The system addresses an unmet need for heart failure patients who cannot benefit from traditional lead-based CRT.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

WiSE CRT System

Phase 3

Indications: Heart failure

Partnerships

No major pharmaceutical or biotech partnerships disclosed; company works with contract manufacturers and may expand manufacturing partnerships as it scales

Beyond the preview

Go deeper on EBR Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EBR Systems.

Explore the full profile